pivot moment approach initi outperform
pt
initi coverag aurinia auph
outperform rate pt ahead phase readout voclosporin
patient lupu nephriti ln aurinia lead asset voclosporin cyclosporin
analog develop ln dri eye syndrom de focal segment
glomerularsclerosi fsg base total data voclosporin includ
extens global phase placebo-control studi believ voclosporin could
becom first therapeut approv treatment ln moreov manag
expertis develop lupu nephriti reflect phase
aurora execut expect read ad voclosporin potenti
address high unmet need ln bullish
approach pivot moment phase aurora encourag
setup global studi complet enrol patient report
septemb assess endpoint complet renal
respons anticip top-lin data becom avail weeks/month
phase aura studi result provid robust evid voclosporin
success aurora consid pivot dose impress complet renal
respons rate compar placebo despit
initi imbal mortal event observ long-term follow-up
month studi highlight overal normal across arm consist
expect set histor ln trial
aurinia team last potenti next team impact
ln treatment paradigm bring leadership experi isotechnika
pharma aspreva lupu manag studi alm know-how
develop voclosporin prior ln studi enabl smooth
execut aurora posit would lend regulatori
commerci activ
ad opportun expand voclosporin de fsg could expand
alreadi larg market opportun ln alon expect initi interim fsg
data de acceler phase studi believ de reflect
opportun meaning data catalyst expect
initi outperform pt pt blend averag
multipl dcf analysi sum-of-the-part valuat
attribut voclosporin potenti ln incorpor
probabl success matur clinic program de contribut
share ascrib discount rate compani
year price histori auph
compani focus diseas high
voclosporin phase develop
treatment lupu nephriti
aurinia base victoria canada
analyst certif import disclosur see disclosur
aurinia focus opportun voclosporin lupu
nephriti dri eye syndrom consid near-term
readout pivot phase lupu nephriti studi anticip
share could re-rat follow posit primari outcom
addit initi pipelin opportun fsg
matur late-stag program dri eye syndrom also
posit stock setup
phase aurora studi meet primari endpoint complet renal
aurinia enrol first patient phase audrey studi
initi phase audrey studi de
initi data phase studi fsg
phase aurora studi meet primari endpoint complet renal
aurinia develop bd/licens agreement voclosporin ex-u
aurinia add addit asset pipelin portfolio
phase aurora studi meet primari endpoint complet
phase aurora studi demonstr safeti signal associ
aurinia initi phase audrey studi
pt blend averag dcf multipl analysi sum-of-the-part valuat attribut voclosporin potenti ln
incorpor probabl success matur clinic program de contribut cash
equival arriv pt ascrib discount rate compani line smid-cap biotech compani
clinic efficaci voclosporin fail meet clinic efficaci endpoint program ln
clinic safeti safeti signal emerg clinic studi voclosporin
manufactur risk manufactur issu could limit penetr commerci market
regulatori risk regul rais addit requir concern around develop delay prevent regulatori approv
commercial/competitive/reimburs risk competit pressur develop asset could lower market potenti
voclosporin negoti payor could limit market opportun ln fsg de
financ aurinia may requir addit fund advanc futur develop potenti commerci voclosporin
late-stag develop biopharmaceut compani focus
treatment immune-rel condit aurinia lead compound voclosporin
develop lupu nephriti ln phase aurora studi voclosporin
cyclosporin analog design maintain activ tradit calcineurin inhibitor
without renal-specif liabil addit ln voclosporin develop focal
segment glomerular sclerosi fsg rare kidney diseas lastli aurinia also
pursu ophthalm solut voclosporin vo pois enter phase
studi audrey dri eye syndrom de later year
initi coverag aurinia outperform rate
price target next month valuat focus aurinia
opportun voclosporin vo lupu nephriti dri eye syndrom
consid near-term readout pivot phase ln studi anticip share
could re-rat follow posit primari outcom addit initi pipelin
opportun fsg matur late-stag program dri eye syndrom
posit stock setup
lupu nephriti challeng diseas treat base multi-factori
natur diseas underli autoimmun condit mani investig
agent fail voclosporin one compound target activ pathway
treatment lupu significantli differenti compound
class calcineurin inhibitor consid sensit ln patient renal toxic
immunosuppress treatment patient remain challeng believ
effect approv therapi indic could signific market potenti
million us alon
invest prospect concentr binari risk play focus
upcom phase readout voclosporin ln anticip read
believ compel phase data aura experienc leadership aurinia
bring isotechnika aspreva lupu manag studi handicap
risk-reward favor pivot event
employ composit valuat methodolog biotechnolog compani util
revenu multipl discount cash flow analysi util initi discount
rate lower late stage commerci averag rate
auph price target assumpt indic exhibit
appli revenu multipl ln estim peak revenu million
million us row respect lie
middl rang industri averag multipl account expans opportun
primarili fsg ex-u territori ascrib royalti rate consid
up-front payment conserv upsid estim
probabl success drug approv voclosporin lupu nephriti
base phase data avail histor success rate phase studi
de ascrib probabl success base result initi safeti
studi potenti advanc phase develop anticip second phase
studi valu program base peak royalti revenu million
million us ex-u respect
appli discount rate auph valuat line smid-cap biotech
compani pt blend dcf multipl valuat
exhibit partsmultipl valuat per share
assumpt multipl tab lupu nephriti nephriti growth cash valu outstand per share per share million except per share programpeak revenuemultipleyearwaccvaluationposrisk-adj valuat /share totalln million except per share assumptionscurr ye share auph outperform
exhibit partsmultipl valuat per share/peak revenu program
risk thesi follow
clinic efficaci voclosporin fail meet clinic efficaci endpoint
program ln
clinic safeti safeti signal emerg clinic studi voclosporin
manufactur risk manufactur issu could limit penetr commerci
regulatori risk regul rais addit requir concern around
develop delay prevent regulatori approv
commercial/competitive/reimburs risk competit pressur
develop asset could lower market potenti voclosporin negoti
payor could limit market opportun ln fsg de
financ aurinia may requir addit fund advanc futur develop
potenti commerci voclosporin
lupu nephriti per name inflammatori diseas kidney mediat
lupu aka system lupu erythematosu sle autoimmun diseas lupu
overactiv immun system affect bodi organ high preval
impact kidney primarili affect women ratio sle vari
preval base ethnic high preval among us black popul
approxim half sle patient expect damag kidney
patient report develop end-stag renal diseas esrd due higher
preval minor popul includ hispan ln account half
esrd case
lupu occur individu genet predisposit expos environment factor
across studi gene hla loci certain allel associ
protect ln increas risk develop ln versu
respect howev interact gene
develop ln remain less understood consequ challeng
sle mediat immun activ manifest presenc autoantibodi
aberr lymphocyt behavior ln activ coincid increas
ifn respons follow neutrophil activ upregul proinflammatori
transcript inflamm present renal function impair lead
elev proteinurea excess protein urin serum creatinas case
sle patient often identifi diagnost test measur
autoantibodi anti-dsdna anti-doubl strand dna anti-smith antibodi
autoantibodi lead format immun complex bind damag renal
exhibit pathophysiolog ln
yap dy nl mol
addit autoantibodi lymphocyt subset suspect contribut
activ diseas motiv explor rituximab therapi poor
respond poor-respond patient activ complement system also
observ prompt investig complement target therapi apelli
pharmaceut complement-depend nephropathi
diagnosi classif lupu nephriti
patient suspect ln diagnost biopsi remain gold standard
detect howev debat rather invas practic due
effect mycophenol mofetil mmf corticosteroid activ across ln
subtyp identifi patient given induct therapi follow mainten
therapi classif ln broken class exhibit corrobor
histolog clinic find lupu nephriti patient present somewhat
heterogen albeit primarili typic proteinurea exhibit
patient class diseas may mild requir signific
treatment class patient sever irrevers renal damag often sever
benefit intervent patient among class treat potent
immunosuppress effort prevent progress chronic kidney diseas
end stage renal diseas signific influenc morbid mortal
exhibit manifest lupu preval
ln patient typic experi acut flare lead worsen renal function need
intervent patient experi flare relaps rang
patient follow induct although cours therapi ln
patient vari one propos algorithm base treatment around renal respons
exhibit propos algorithm ln therapi
alm studya major learn ln
common treatment induct mainten therapi high-dos
corticosteroid address inflamm combin cyclophosphamid mmf
intens induct therapi explor establish larg studi
aspreva lupu manag studi alm compar mmf therapi
intraven cyclophosphamid noninferior basi
alm patient grade ln random receiv mmf
combin background corticosteroid therapi week treatment patient
treat mmf demonstr compar rate renal respons defin
urinari protein creatinin ratio upcr stabil improv creatinin
approxim half patient mmf-treat patient ivc-treat
patient achiev type renal respons approxim
respect achiev stringent complet respons overal
superior establish trial effect mmf legitim
found superior among non-asian/non-whit patient exhibit
exhibit almsrespons rate ethnic
alm quit establish mmf broad superior denot prior
treatment algorithm result establish recommend ethnic subset
diseas importantli result also provid understand manag
patient expect around typic respons rate standard
care treatment manag steroid taper exhibit chronic long-term oral
corticosteroid associ signific morbid includ osteoporosi glucos
intoler hypertens moreov use combin
immunosuppress greatli rais infect risk said great major
ln patient long-run requir new treatment due refractori diseas
inadequ respons mmf
use calcineurin inhibitor cni previous explor howev
current avail treatment cyclosporin tacrolimu reserv
refractori diseas case due liabil worsen renal function case
cyclosporin increas risk glucos intoler case tacrolimu
moreov cyclosporin contraind mmf due inhibit
mycophenol acid activ metabolit drug potenti believ off-target
effect calcineurin inhibitor
voclosporin novel drug analog cyclosporin design potent inhibit
calcineuirn enzym achiev stabl drug plasma concentr level exhibit
origin isotechnika voclosporin licens aurinia januari use
ln
follow initi promis result phase pilot studi aurion
enrol adult ln patient class class
random receiv twice-daili voclosporin placebo
combin background mmf treatment taper steroid dose exhibit
order qualifi studi patient exhibit sign activ nephriti via
proteinurea level greater case class
patient primari endpoint studi assess complet renal respons
rate defin upcr less equal mainten low-
dose steroid week stabl egfr greater equal
confirm decreas baselin greater equal absenc rescu
renal health egfr selena-sledai diseas score durat respons well
safeti toler week
exhibit design phase aura studi
studi patient treat low dose voclosporin bid
demonstr widen improv complet remiss rel control follow
treatment patient treat
voclosporin bid respect achiev complet remiss compar
placebo-tr patient result improv demonstr
complet remiss rate voclosporin-tr patient versu
placebo-tr patient lower threshold respons partial respons rate
voclosporin also consist signific rel control rate
put mortal event bed
wrinkl initi data voclosporin observ imbal
mortal event activ treat arm exhibit first week
treatment death report low-dos treatment cohort due
number vari caus type overal rate death uncommon
ln trial imbal rel placebo treat cohort one death rais
exhibit phase mortal event rel histor studi ln
two import observ deeper assess aura studi
posit mortal event first patient enter studi
aura came studi sever baselin characterist measur
proteinurea reflect cohort subset low dose voclosporin
vc highest baselin level mmf lowest exhibit left
moreov assess death observ signific proport event
occur site countri standard care potenti compromis
exhibit right order prevent clinician bia random done site
level lead imbal patient activ drug particular bangladesh
seven death occur activ vcs-treat arm
exhibit support evid mortal imbal baselin characterist random
recent era-edta june long-term follow-up conclus aura
demonstr signific rebalanc event report death among
placebo-tr placebo patient versu one patient vc low dose arm
death high dose arm result consist consid poor renal
outcom progress esrd dialysi transplant exhibit per prior
observ compromis access care event occur
identifi site russia/phillippines/sri lanka bangladesh strengthen
rational previous observ imbal potenti avoid situat
on-going phase studi
death trigger dsmb review death phase studi
deem relat studi drug moreov studi conduct without interrupt
also import note voclosporin investig across number
indic patient dose greater equal pivot phase dose
higher
auroraa studi cover
follow discuss fda ema japanes regulatori author pmda
aurinia initi singl phase aurora studi lupu nephriti investig
bid voclosporin placebo background mmf therapi aurora phase
studi enrol subject random across countri
complet late last septemb readout expect primari
endpoint studi assess complet renal respons week measur
similar criteria associ phase aura studi low-dos steroid last
week week note studi initi target enrol patient
swiftli exceed due patient demand
follow aurora patient enter blind two-year continu studi
assess long-term follow-up patient renal biopsi extens studi
expect roll approxim two-third aurora studi base previou
experi studi alm complet renal respons critic clinic
goal patient believ long-term follow-up treatment experi
patient popul better inform commerci real-world experi
near pure ln de option
aurinia commerci potenti driven lead potenti lupu nephriti
proxim aurora readout posit result could significantli posit compani
emerg commerci play diseas area approv therapi
inadequ standard care said market dynam ln complex
ascrib conserv assumpt number assumpt
arriv peak revenu opportun million us ln could
upsid blockbust level implic certain conserv assumpt loosen
ln affect higher proport individu person
net price exce estim attempt peg
brand immun modul reflect valu closer treatment
cost diseas burden orphan price
altern treatment option fail place greater share market auph
current assumpt
exhibit revenu opportun voclosporin vo
million
ln stori go post-aurora
follow aurora expect greater clariti rest long-term market opportun
voclosporin initi primari readout provid sens opportun
expect blind long-term extens studi better character real-world
treatment ln patient extent voclosporin incorpor
treatment regimen area interest post-data includ
long ln patient treat voclosporin annual treatment cost
model preval incid market
voclosporin treatment reserv primarili patient experi activ ln
flare penetr address market
potenti price rare/near-rar indic potenti depend long-
emerg path forward de
optim calcineurin inhibitor ophthalm solut voclosporin vo
develop dri eye syndrom de cyclosporin emuls formul
alreadi approv diseas restasi et al audrey matur aurora
studi read anticip aspect invest stori attract attent
aurinia conduct phase studi vo order compar
head-to-head safeti efficaci vo versu restasi studi
enrol patient administ twice daili vo restasi double-mask
random day eye studi unabl demonstr
separ arm discomfort one initi object vo potenti
cyclosporin analog manifest abil administ higher concentr
without chang toler investig dose treatment led statist
clinic relev improv respond rate improv four week
measur schirmer tear test compar restasis-tr
patient exhibit associ measur fluorescein corneal stain
fc symptom assess dri sand score consist
exhibit phase result de
follow phase safeti studi aurinia plan initi phase dose-rang
audrey studi vo studi enrol approxim patient
random receiv either vo bid vehicl control
exhibit primari outcom studi assess improv
schirmer tear test four week secondari measur week
fluorescein corneal stain symptom dri eye safeti studi assess
best clinic dose potenti establish differenti onset activ vo
compar formul cyclosporin
follow readout audrey anticip aurinia engag fda potenti
path forward approv vo de expect includ second phase
studi novel agent outsid cyclosporin sought approv base
primari endpoint analysi sign symptom de flexibl could exist vo
posit cyclosporin analog model incorpor feasibl develop
timelin amen potenti outcom
option fsg
expans opportun voclosporin compani pursu develop
focal segment glomerulosclerosi rare kidney diseas similar diseas
characterist ln due voclosporin target engag podocyt
treatment voclosporin believ disrupt observ inflamm kidney
protect kidney function initi result phase proof concept studi
anticip exhibit
enter auph enter period diversifi catalyst next
phase aurora studi readout
initi phase audrey studi
initi result audrey
potenti licens bd opportun voclosporin vo ex-u
market
aurinia divers pipelin indic attract signific attent biotechnolog
develop consid high unmet need patient opportun novel
agent achiev meaning clinic well commerci impact provid brief
summari competit agent ln de fsg
develop phase studi patient
iga nephropathi lupu nephriti primari membran nephropathi
glomerulopathi glomerulonephr dens deposit diseas
synthet cyclic peptid conjug polyethylen glycol polym
binds/inhibit specif block three pathway complement
activ classic lectin altern also studi phase
studi patient paroxysm nocturn hemoglobinuria pnh phase studi
patient geograph atrophi ga phase studi autoimmun hemolyt
anemia aiha initi result complement depend nephropathi expect
american societi nephrolog kidney week novemb
iscalimab novarti develop phase studi patient
moder activ prolif lupu nephriti administ
top standard care therapi mycophenol mofetil mmf corticosteroid
lupu nephriti fulli human monoclon antibodi prevent pathway
signal activ cell type antibodi block
mediat inflammatori respons well-advanc mechan potenti treat
bristol-my squibb develop phase studi
patient lupu nephriti oral select tyrosin
kinas inhibitor mediat cytokine-driven immun pro-inflammatori signal
pathway includ type ifn-driven respons signal
implic pathophysiolog variou autoimmun disord also
studi phase studi patient moder sever plaqu psoriasi
belimumab glaxosmithklin develop belimumab phase studi patient
activ lupu nephriti belimumab administ top standard
care therapi mycophenol mofetil mmf corticosteroid lupu nephriti
belimumab fulli human recombin monoclon antibodi blys-specif
inhibitor bind solubl bli bind cell directli inhibit surviv
 cell includ autoreact cell thu indirectli reduc differenti
cell igg-produc plasma cell belimumab benlysta also first approv
medicin us children system lupu erythematosu sle could
anifrolumab astrazeneca develop anifrolumab phase studi patient
activ prolif lupu nephriti anifrolumab administ top
standard care therapi mycophenol mofetil mmf corticosteroid lupu
nephriti anifrolumab fulli human monoclon antibodi bind subunit
type interferon receptor block activ type interferon includ ifn- ifn-
ifn- cytokin involv inflammatori pathway shown
associ lupu nephriti
develop phase studi patient
mycophenol mofetil mmf prednison administ
top standard care therapi mycophenol mofetil mmf corticosteroid
lupu nephriti select immunoproteasom inhibitor select
target subunit immunoproteasom shown broad anti-
inflammatori respons sever autoimmun diseas preclin model phase
result healthi volunt show potenti avoid advers effect caus
current market non-select proteasom inhibitor also studi
studi patient system lupu erythematosu sle dermatomyos
dm polymyos pm autoimmun hemolyt anemia aiha immun
obinutuzumab roch develop obinutuzumab phase studi patient
prolif lupu nephriti sn/rp class iv result
obinutuzumab administ top standard care therapi mycophenol mofetil
mmf mycophenol acid mpa corticosteroid lupu nephriti
obinutuzumab gazyva monoclon antibodi bind
studi met primari key secondari endpoint proport particip
achiev protocol-defin complet renal respons crr week primari
endpoint met improv overal renal respons defin complet partial
renal respons improv measur diseas activ measur
blood serum lab valu also shown obinutuzumab also approv
chemotherapi treatment patient chronic lymphocyt leukemia lymphoma
bi boehring inglheim develop bi add-on-therapi
standard care treatment phase studi patient activ lupu nephriti
bi administ top standard care therapi
mycophenol mofetil mmf mycophenol acid mpa corticosteroid lupu
nephriti bi antagonist antibodi mediat t-cell depend
b-cell igg isotyp switch bind highli express b-cell
associ pathogenesi autoimmun diseas phase result healthi
volunt show bi well toler high potenti block
develop phase studi initi
august post fda top line data expect end
resubmiss nda expect patient dri eye diseas
keratoconjunct sicca ophthalm
corticosteroid formul util kala ampplifi mucus-penetr particl
mpp drug deliveri technolog enhanc penetr loteprednol etabon le
target tissu eye studi two previou phase studi stride
stride
reproxalap develop reproxalap phase studi
patient dri eye diseas reproxalap novel immune-modul
rasp reactiv aldehyd speci inhibitor rasp bind thiol sulfur-contain
amin nitrogen-contain residu protein coval result rasp-protein
adduct influenc function protein activ intracellular inflammatori factor
includ nf-kb import mediat inflammatori respons reproxalap work
lower level rasp believ elev ocular system
inflammatori diseas reproxalap success phase studi
posit result report septemb patient treat concentr
reproxalap statist signific reduct four-symptom ocular dryness
score overal ocular discomfort symptom score follow
first part two-part phase renew trial dri eye diseas expect
complet
regentre jv regenerx develop phase studi
patient dri eye diseas
steril preservative-fre eye drop preclin studi increas
product thu promot cell migrat increas cell-cel cell-matrix
contact result apoptosi inflamm cornea reduc
previou phase studi dri eye diseas demonstr drug-rel
seriou advers event well statist signific improv sign
symptom dri eye current run phase studi expect complet
mitotech develop phase studi patient dri eye diseas
cardiolipin peroxid inhibitor mitochondrial-target
antioxid presenc mitochondri membran enabl mitochondria
protect reactiv oxygen speci ro break chain reaction lipid
destruct thu treat inflamm associ dri eye diseas visomitin
product alreadi approv dri eye diseas russia
ocugen develop investig twice-daili steroid-fre
preservative-fre eye drop brimonidin tartrat phase studi patient
dri eye diseas brimonidin tartrat rel select
adrenerg receptor agonist peak ocular hypotens effect nonclin model
suggest brimonidin tartrat dual mechan action reduc aqueou
humor product increas uveoscler outflow brimonidin tartrat approv
fda patient open-angl glaucoma ocular hypertens
earli potenti therapeut benefit observ phase studi
develop phase studi patient dri
eye diseas select nicotin acetylcholin receptor
nachr agonist activ trigemin parasympathet pathway promot
natur tear film product previou two phase studi primari tear
product measur schirmer score day secondari endpoint patient-
report symptom ded measur dryness scale ed day
day met
develop phase studi patient dri eye
diseas protein deriv silk protein dual-
mechan action physic improv tear film stabil reduc inflamm
inher enhanc spread wet properti aqueou formul
hydrophob surfac inhibit kinas activ nf-b gene transcript
sparsentan develop sparsentan phase studi initi top
line expect patient primari genet focal segment
glomerulosclerosi fsg sparsentan dual endothelin type eta
angiotensin ii type receptor antagonist dual mechan action
combin angiotensin receptor blockad endothelin receptor type blockad
success phase studi duet posit result patient random
patient receiv studi drug mg/d rest receiv irbesartan
mg/d treatment sparsentan result greater reduct urinari protein-to-
creatinin ratio up/c compar irbesartan dose cohort percent
versu percent combin mg dose cohort
percent vs percent combin sparsentan also phase
studi patient igan top-lin efficaci data expect
develop phase studi patient
focal segment glomerulosclerosi fsg nephrot syndrom two subtyp
fsg oral chemokin receptor inhibitor
often express monocyt macrophag associ mani
autoimmun inflammatori diseas produc posit result phase
studi patient diabet nephropathi well-toler
complexa inc develop phase studi patient primari
focal segment glomerulosclerosi fsg oral nitrat
fatti acid compound acid impact fibrot
inflammatori pathway includ upregul pathway inhibit
nuclear factor-kappa toll-lik receptor pathway shown
toler safe subject previou five phase studi show
inhibit key biomark disease-rel inflamm fibrosi also
evalu phase studi patient pulmonari arteri hypertens
develop phase studi patient
primari focal segment glomerulosclerosi fsg
antagonist undisclos target treatment nephrot syndrom
evalu phase studi previous healthi volunt
propagermanium dimerix bioscienc develop propagermanium phase studi
patient primari focal segment glomerulosclerosi fsg
receiv irbesartan propagermanium bi sesquioxid
carboxyethylgermasesquioxan altern medicin
development-stag biotechnolog compani focus
clinic develop voclosporin requir capit execut clinic studi
fund oper aurinia conduct privat placement secondari offer
septemb aurinia complet merger isotechnika privat
placement unit compris one common share one half full
warrant price per unit gross proce million share
began trade ticker aup toronto stock exchang septemb
aurinia list exchang well june
compani hold cash equival balanc million believ
provid cash runway
recent novemb enter open
market sale agreement establish at-the-market atm facil februari
complet sale common share
weight averag price aggreg gross proce approxim
million close atm facil
june aurinia report option exercis includ
valuat model model futur capit rais order support futur clinic
commerci develop voclosporin vo
peter greenleaf mbachief execut offic director
mr peter greenleaf current serv chief execut offic member
board director inc effect april march
april mr greenleaf serv chief execut offic inc
remain board director inc serv member
board director sinc may march februari mr greenleaf
serv ceo chairman sucampo pharmaceut inc june
march mr greenleaf serv ceo member board director
histogen corpor regen medicin compani
employ medlmmun llc global biolog arm astrazeneca
recent serv presid januari june mr greenleaf also serv
presid medlmmun ventur wholli own ventur capit fund within
astrazeneca group prior serv presid medlmmun mr greenleaf
senior vice presid commerci oper compani respons
commerci corpor develop strategi function also held senior
commerci role centocor inc jansen biotechnolog johnson johnson
boehring mannheim roch hold mr
greenleaf earn degre st joseph univers degre
dr solomon co-found privately-held dr solomon
join aurinia vifor pharma formerli held
posit vice presid research develop lead clinician
develop cellcept rare diseas dr solomon led cellcept clinic
develop team peopl saw complet report public
studi pemphigu vulgari myasthenia gravi industri first
success landmark lupu nephriti studi call aspreva lupu manag studi
alm respons clinic develop activ phase
well particip formul strategi portfolio manag due
dilig effort prior vifor aspreva dr solomon held varieti posit
roch global clinic develop medic affair transplant virolog
auto-immun diseas roch dr solomon led divers team
develop implement post-market studi budget exceed
million transplant cellcept zenapax virolog cytoven
franchis dr solomon qualifi medicin receiv mb bs md guy
hospit medic school london subsequ work physician london uk
complet specialist train anesthesia intens care research interest
includ sepsi chronic pain
mr martin current chief oper offic aurinia inc
formerli ceo director co-found privately-held aurinia pharmaceut inc
merg former isotechnika pharma inc mr martin join aurinia
vifor pharma held posit director global busi develop
licens prior vifor mr martin key member busi develop team
saw aspreva sold galenica upon join aspreva mr martin
initi strateg launch plan process cellcept less-common
autoimmun diseas includ indic pemphigu vulgari
myasthenia gravi lupu nephriti prior mr martin held varieti
progress senior commerci posit schering-plough recent
respons rheumatolog busi unit remicad franc role
full profit loss respons direct respons sale team
market team infus access team addit schering-plough mr
martin brand manag respons canadian launch remicad
infliximab ultim becam success product launch canadian
histori mr martin start career industri sale organ schering-
plough receiv multipl award recognit rapidli progress
toward prior mention role
mr bourgeault chief offic compani sinc
respons financi administr oper compani
tenur contribut significantli one largest canadian biotechnolog pipe
transact total million involv multi-million dollar roch
licens agreement voclosporin addit play crucial role
execut merger isotechnika privately-held
septemb six year prior join isotechnika control
privat industri distribut compani senior manag public account
kpmg mr bourgeault obtain charter account design
dr huizinga year pharmaceut develop experi
manag global clinic develop voclosporin sinc
isotechnika pharma inc prior merger aurinia join
industri dr huizinga investig nephrolog transplant clinic trial
univers alberta divis nephrolog immunolog involv
clinic trial phase phase iv success
develop numer compound includ cellcept neoral prograf aranesp
simulect act consult nephrolog transplant
pharmaceut compani lectur extens recogn expert
immunosuppress drug develop dr huizinga numer articl publish
lead medic journal includ new england journal medicin lancet
american journal transplant member mani profession societi
relat nephrolog transplant nurs founder renalpro
moder forum renal profession dr huizinga hold sc medicin
epidemiolog univers alberta phd organiz leadership
regent univers certifi nephrolog member sigma theta tau honor
societi nurs hold certif leadership equip leadership
glenn schulman pharmd mphsvp corpor investor relat
glenn schulman healthcar profession nearli twenti year advis biotech
life scienc compani prior join aurinia dr schulman led corpor
commun investor relat inc prior
achillion dr schulman held posit increas respons curagen corp
ultim respons aspect corpor medic commun
investor public relat dr schulman receiv bs pharmaci philadelphia
colleg pharmaci doctor pharmaci degre rutger ernest mario school
pharmaci complet post-doctor fellowship memori sloan-kett cancer
center dr schulman receiv mph health manag yale univers
stock price compani mention report
inc kala-nasdaq outperform esther rajavelu
statement oper
thousand except per share
research develop revenu
research develop
good sold
corpor administr busi develop
amort acquir intellectu properti intang asset
amort properti equip
loss chang deriv warrant liabil tax
chang estim fair valu deriv warrant liabil
loss incom tax
net loss period
net chang fair valu short-term invest
net comprehens loss period
basic dilut loss per common share
weight average common share basic dilut
statement oper
thousand
cash equival
account receiv accru interest receiv
prepaid expens deposit
properti equip
acquir intellectu properti intang asset
liabil stockhold equiti
account payabl accru liabil
provis restructur cost
accumul comprehens loss
total liabil stockhold equiti
statement oper
thousand
amort defer revenu
depreci properti equip
amort acquir intellectu properti intang asset
chang short term invest discount
revalu conting consider
foreign exchang impact leas liabil
share issu cost alloc deriv warrant
chang estim fair valu deriv warrant liabil
sale equip
chang provis restructur cost
net chang oper asset liabil
net cash use oper activ
proce matur short term invest
purchas short term invest
proce sale equip
purchas equip
net cash gener use invest activ
net proce issuanc common share
net proce issuanc bought deal unit
net proce issuanc privat placement unit
share issu cost relat issuanc unit
proce exercis deriv warrant
proce exercis warrant
proce exercis stock option
princip element leas payment
net cash provid financ activ
net increas decreas cash equival
cash equival begin period
cash equival end period
exhibit revenu model lupu nephriti dri syndrom
total us patient sle
total us patient ln
ln patient treat voclosporin
preval sle per
preval ln per
total row patient sle
total row patient ln
row eu patient treat voclosporin
preval sle per
preval ln per
exhibit revenu model lupu nephriti dri syndrom
total us patient de
de patient treat vo
preval de us
total eu patient de
de patient treat vo
preval de us
price discount us
